[go: up one dir, main page]

MX2016016612A - Formulaciones estables de undecanoato de testosterona. - Google Patents

Formulaciones estables de undecanoato de testosterona.

Info

Publication number
MX2016016612A
MX2016016612A MX2016016612A MX2016016612A MX2016016612A MX 2016016612 A MX2016016612 A MX 2016016612A MX 2016016612 A MX2016016612 A MX 2016016612A MX 2016016612 A MX2016016612 A MX 2016016612A MX 2016016612 A MX2016016612 A MX 2016016612A
Authority
MX
Mexico
Prior art keywords
testosterone undecanoate
stable formulations
directed
present
pharmaceutical formulations
Prior art date
Application number
MX2016016612A
Other languages
English (en)
Other versions
MX373197B (es
Inventor
G Schoonus-Gerritsma Gerritdina
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016016612A publication Critical patent/MX2016016612A/es
Publication of MX373197B publication Critical patent/MX373197B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a formulaciones farmacéuticas estables; más específicamente, la presente invención se relaciona con formulaciones farmacéuticas estables de undecanoato de testosterona.
MX2016016612A 2014-06-17 2015-06-15 Formulaciones estables de undecanoato de testosterona. MX373197B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14172805 2014-06-17
PCT/EP2015/063292 WO2015193224A1 (en) 2014-06-17 2015-06-15 Stable formulations of testosterone undecanoate

Publications (2)

Publication Number Publication Date
MX2016016612A true MX2016016612A (es) 2017-03-20
MX373197B MX373197B (es) 2020-05-12

Family

ID=50980940

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016612A MX373197B (es) 2014-06-17 2015-06-15 Formulaciones estables de undecanoato de testosterona.

Country Status (12)

Country Link
US (1) US9925200B2 (es)
EP (1) EP3157505B1 (es)
JP (1) JP6618488B2 (es)
KR (1) KR20170020779A (es)
CN (1) CN106456782B (es)
AU (1) AU2015276321B2 (es)
BR (1) BR112016028192A2 (es)
CA (1) CA2950670A1 (es)
ES (1) ES2749008T3 (es)
MX (1) MX373197B (es)
RU (1) RU2708238C2 (es)
WO (1) WO2015193224A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011082384A2 (en) 2009-12-31 2011-07-07 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
NZ631833A (en) 2013-03-15 2017-06-30 Differential Drug Dev Ass Llc Emulsion formulations
IL274893B2 (en) 2017-11-27 2024-08-01 Umecrine Cognition Ab Pharmaceutical formulation of 3 alpha-ethynyl-3 beta--hydroxyandrostan-17-one oxime
CA3107214A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098802A (en) 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
US4147783A (en) 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL189235C (nl) 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
NL7510104A (nl) 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
FI920646A7 (fi) 1989-08-17 1992-02-14 Cortecs Ltd Farmaseuttiset aineet
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
RU2211021C2 (ru) 1997-07-29 2003-08-27 Фармация Энд Апджон Компани Фармацевтическая самоэмульгирующая композиция и ее носитель для липофильных фармацевтически активных агентов
US7396526B1 (en) * 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
RU2246296C2 (ru) 1999-04-01 2005-02-20 Акцо Нобель Н.В. Композиция, включающая ундеканоат тестостерона и касторовое масло
RU2303981C2 (ru) * 2000-11-01 2007-08-10 Юнимед Фармасьютикалс, Инк. Способ лечения эректильной дисфункции и повышения либидо у мужчин
US20070298099A1 (en) * 2004-11-24 2007-12-27 Peresypkin Andrey V Liquid and Semi-Solid Pharmaceutical Formulations for Oral Administration of a Substituted Amide
PL2985026T3 (pl) 2005-04-15 2023-02-20 Clarus Therapeutics, Inc. Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
WO2011082384A2 (en) * 2009-12-31 2011-07-07 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
CN102883710B (zh) 2010-04-12 2014-09-10 克劳拉斯医疗有限公司 口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120135074A1 (en) 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
CA2905703A1 (en) 2013-03-15 2014-09-18 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
WO2015100406A1 (en) 2013-12-26 2015-07-02 Clarus Therapeutics, Inc. Use of oral pharmaceutical products combining testosterone esters with hypolipidemic agents

Also Published As

Publication number Publication date
AU2015276321B2 (en) 2019-10-24
MX373197B (es) 2020-05-12
RU2708238C2 (ru) 2019-12-05
AU2015276321A1 (en) 2016-11-10
ES2749008T3 (es) 2020-03-18
JP2017522283A (ja) 2017-08-10
EP3157505B1 (en) 2019-07-24
US9925200B2 (en) 2018-03-27
CN106456782A (zh) 2017-02-22
JP6618488B2 (ja) 2019-12-11
RU2017101240A (ru) 2018-07-17
WO2015193224A1 (en) 2015-12-23
BR112016028192A2 (pt) 2017-08-22
CA2950670A1 (en) 2015-12-23
RU2017101240A3 (es) 2019-02-22
KR20170020779A (ko) 2017-02-24
CN106456782B (zh) 2020-02-18
US20170136033A1 (en) 2017-05-18
EP3157505A1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2021014956A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
TW201614041A (en) Compositions for electronic devices
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
TWD171711S (zh) 端子
PH12017500836A1 (en) Transdermal formulations
IN2013MU00848A (es)
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
IN2013MU03641A (es)
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
SG10201900598TA (en) Factor viii formulation
IN2014CH00840A (es)
MX2016016612A (es) Formulaciones estables de undecanoato de testosterona.
IN2014CH00151A (es)
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
NZ721832A (en) Solid forms of tenofovir
PH12018501166B1 (en) Concentrated gibberellin solution formulations
MA40444A (fr) Procédé de préparation de formulations de poudre sèche
MX2015015850A (es) Composiciones de sabor y fragancia que contienen tiopiran-carbaldehido.
EA201692453A1 (ru) Способ получения ингаляционных составов
IN2013MU03768A (es)
UA104671U (uk) Застосування яктону як нейропротектора
IN2014CH00872A (es)

Legal Events

Date Code Title Description
FG Grant or registration